Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Biocon

    Tag: Biocon

    You Searched For "Biocon"
    Biocon gets USFDA EIR with VAI Classification for its Malaysian Insulin Manufacturing Facility

    Biocon gets USFDA EIR with VAI Classification for its Malaysian Insulin Manufacturing Facility

    Medical Dialogues Bureau1 April 2020 7:14 AM GMT
    Bengaluru: Biocon Sdn Bhd, a subsidiary of Biocon Limited has announced that it has received the Establishment Inspection Report (EIR) from the U.S....
    Biocon, Mylan win patent rights for Insulin Glargine Device against Sanofi

    Biocon, Mylan win patent rights for Insulin Glargine Device against Sanofi

    Medical Dialogues Bureau12 March 2020 5:59 AM GMT
    Insulin Glargine is a long-acting insulin used to treat adults with Type 2 diabetes and adults and paediatric patients with Type 1 diabetes for the...
    USFDA Accepts Biocon, Mylans application for review of   Proposed Biosimilar of Bevacizumab

    USFDA Accepts Biocon, Mylan's application for review of Proposed Biosimilar of Bevacizumab

    Medical Dialogues Bureau10 March 2020 7:45 AM GMT
    Biocon Ltd. and Mylan N.V. announced that the U.S. Food and Drug Administration (FDA) has accepted Mylan's Biologics License Application (BLA)...
    Biocon Small Molecules API Manufacturing Facility Completes Post -Approval and GMP USFDA Inspection

    Biocon Small Molecules API Manufacturing Facility Completes Post -Approval and GMP USFDA Inspection

    Medical Dialogues Bureau29 Feb 2020 6:05 AM GMT
    New Delhi: Drug API maker, Biocon has informed that the U.S. Food and Drug Administration (FDA) conducted a Post-Approval and GMP inspection of Small...
    Biocon Bengaluru facility clears USFDA inspection

    Biocon Bengaluru facility clears USFDA inspection

    Farhat Nasim21 Jan 2020 7:30 AM GMT
    The US Food and Drug Administration (USFDA) conducted a pre-approval inspection of the oral solid dosage manufacturing facility of Biocon Pharma, a...
    Biocon gets EIR from USFDA for Bengaluru biologics unit

    Biocon gets EIR from USFDA for Bengaluru biologics unit

    Medical Dialogues Bureau6 Nov 2019 3:49 AM GMT
    New Delhi: Biopharmaceutical firm Biocon on Tuesday said it has received an establishment inspection report (EIR) from the US health regulator for its...
    Biocon, Mylan launch insulin biosimilar Semglee in Australia

    Biocon, Mylan launch insulin biosimilar Semglee in Australia

    Medical Dialogues Bureau3 Oct 2019 10:21 AM GMT
    New Delhi: Biotechnology major Biocon and pharmaceutical company Mylan N V on Thursday announced the launch of their insulin biosimilar Semglee,...
    Biocon gets USFDA Form 483 with 8 observations for 2 new facilities in Bengaluru

    Biocon gets USFDA Form 483 with 8 observations for 2 new facilities in Bengaluru

    Medical Dialogues Bureau23 Sep 2019 4:45 AM GMT
    "At the conclusion of the inspection, we received a Form 483 with four observations for the new Drug Substance facility, three observations for the...
    Biocon Chief Kiran Shaw, FM Nirmala Sitharaman in tiff over E-Cigarette ban

    Biocon Chief Kiran Shaw, FM Nirmala Sitharaman in tiff over E-Cigarette ban

    Farhat Nasim20 Sep 2019 11:31 AM GMT
    New Delhi: Biocon Chief Kiran Mazumdar Shaw recently got into a spat with the Finance Minister Nirmala Sitharaman on Thursday. The minister defended...
    Biocon inks license, supply pact with CMS for 3 generic formulations

    Biocon inks license, supply pact with CMS for 3 generic formulations

    Medical Dialogues Bureau13 Sep 2019 9:15 AM GMT
    Under the terms of the agreement, Biocon will be responsible for the development, manufacturing and supply of the products and China Medical System...
    We need measures to save jobs in Automotive Sector: Biocon MD Kiran Mazumdar Shaw

    We need measures to save jobs in Automotive Sector: Biocon MD Kiran Mazumdar Shaw

    Medical Dialogues Bureau11 Sep 2019 4:00 AM GMT
    "Passenger Vehicle Sales See Worst Ever Monthly Drop Since 1997-98 - we need measures that r not abt saving auto sector but abt saving 50% of...
    Syngene, Narayana Health, AIF launch CHAMPS- unique initiative to prevent, manage early onset of NCDs

    Syngene, Narayana Health, AIF launch CHAMPS- unique initiative to prevent, manage early onset of NCDs

    Medical Dialogues Bureau15 Aug 2019 4:00 AM GMT
    The combined synergies of Narayana Health as a knowledge partner, Syngene and Biocon Foundation as funding partners and Agastya International as the...
    Next

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier

    This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

    Search only trustworthy HONcode health websites:

    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

    © 2020 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok